Development and Characterization of Repaglinide loaded blend Microsphere

Abstract

The current study aimed to develop controlled-release tablets of Repaglinide utilizing blend microspheres comprising two or more polymers. Repaglinide, a widely used anti-diabetic drug, is known for its relatively short plasma half-life of approximately 3-4 hours, necessitating frequent dosing to maintain therapeutic blood levels for long-term diabetes treatment. To address this limitation, various strategies have been explored to enhance Repaglinide's bioavailability and extend its drug release profile, thus reducing the need for frequent dosing. One such approach is the use of blend microspheres in the formulation of controlled-release tablets.